- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Guggenheim stuft Jade Biosciences nach Transformation auf Kaufen hoch | 1 | Investing.com Deutsch | ||
| Mo | Guggenheim upgrades Jade Biosciences stock rating to Buy on transformation | 1 | Investing.com | ||
| 09.06. | Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy | 1 | GlobeNewswire (USA) | ||
| JADE BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 02.06. | Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress | 1 | GlobeNewswire (USA) | ||
| 14.05. | Jade Biosciences, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 09.05. | Pre-market Movers: ZK International, Jade Biosciences, Twin Vee Powercats, Corvus Pharmaceuticals, Iovance Biotherapeutics | 976 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green ZK International Group Co., Ltd. (ZKIN) is up over... ► Artikel lesen | |
| 05.05. | Stifel initiates Jade Biosciences stock with a Buy, $19 target | 2 | Investing.com | ||
| 02.05. | TD Cowen starts Jade Biosciences coverage with Buy rating | 5 | Investing.com | ||
| 01.05. | Jade Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | RTW Biotech Opportunities' Jade Biosciences merges with Aerovate Therapeutics | 1 | QuotedData | ||
| 30.04. | RTW Biotech Opp. - Jade Biosciences merges with Aerovate Therapeutics | - | RNS | ||
| 25.04. | Aerovate Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 21.04. | Aerovate Therapeutics Stockholders Approve Merger Proposal With Jade Biosciences | 2 | RTTNews | ||
| 21.04. | Aerovate Therapeutics approves reverse split ahead of Jade merger | 1 | Investing.com | ||
| 21.04. | Aerovate Therapeutics genehmigt Aktienzusammenlegung vor Fusion mit Jade | 13 | Investing.com Deutsch | ||
| 21.04. | Aerovate Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.04. | Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals | 197 | PR Newswire | -Aerovate Board of Directors approves 1-for-35 reverse stock split-
WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE)... ► Artikel lesen | |
| 09.04. | Aerovate Therapeutics announces $69.6 million special dividend | 2 | Investing.com | ||
| 09.04. | Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences | 148 | PR Newswire | Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share
WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq:... ► Artikel lesen | |
| 07.04. | Aerovate Therapeutics signals cash dividend ahead of Jade merger | 1 | Investing.com |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 31,400 | -0,63 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 10-Jun-2025 / 09:06 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| QIAGEN | 40,555 | +0,68 % | Qiagen NV-Aktie mit leichten Kursgewinnen (40,955 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Die Aktie kostete zuletzt 40,96 Euro. Ein Kursanstieg in Höhe von 0,275 Euro erfreut derzeit die Aktionäre von Qiagen NV. Aktuell kostet das Papier 40,96... ► Artikel lesen | |
| NOVAVAX | 5,584 | +0,23 % | Novavax slips as Citi launches with Sell rating on pipeline concerns | ||
| STRYKER | 325,60 | -0,15 % | Kursverluste für den Anteilsschein von Stryker (324,9152 €) | Der Anteilsschein von Stryker notiert am Dienstag leichter. Zuletzt zahlten Investoren für die Aktie 374,39 US-Dollar. Ein Verlust von 0,72 Prozent steht gegenwärtig für die Stryker-Aktie zu Buche.... ► Artikel lesen | |
| ILLUMINA | 78,61 | +0,03 % | Zukunftsmarkt - hier geht es um 50 Mrd. USD: Illumina, Moderna, PanGenomic Health | Medizin wird persönlich. Die Zeit, in der Medikamente allen helfen sollen, naht ihrem Ende. Die Experten von BCC Research gehen davon aus, dass der Markt für personalisierte Medizin zwischen 2023 und... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 38,600 | +0,52 % | Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? | ||
| AAP IMPLANTATE | 1,380 | -6,12 % | aap Implantate AG: Online-Präsentation für Investoren am 01.07.2025 | aap Implantate AG ist ein weltweit tätiges Medizintechnikunternehmen mit Sitz in Berlin, Deutschland. Es entwickelt, produziert und vertreibt Produkte für die Traumatologie. Zum durch Patente geschützten... ► Artikel lesen | |
| OCUGEN | 0,907 | 0,00 % | Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST-Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,405 | -0,15 % | SANGAMO THERAPEUTICS, INC - 8-K, Current Report | ||
| INTELLIA THERAPEUTICS | 7,854 | -1,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy ... | With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| EDITAS MEDICINE | 1,876 | -2,90 % | Editas Medicine Is Great. Here's Why You Shouldn't Buy It. | ||
| DEFENCE THERAPEUTICS | 0,476 | -1,24 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,726 | -0,48 % | BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report | ||
| KUROS BIOSCIENCES | 27,900 | +3,18 % | Laura Rosa ist neue Senior Vice President of Global Human Resources bei Kuros |
Das Unternehmen JADE BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +5,85 % bei einem Aktienkurs von 9,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JADE BIOSCIENCES INC finden Sie auf Wallstreet Online.